Yarrow Bioscience Announces Proposed Underwritten Public Offering
Yarrow Bioscience has commenced an underwritten public offering of common stock, with pre-funded warrants available in lieu of shares for certain investors. Size and price were not disclosed, and underwriters receive a 30-day option to buy up to an additional 15% of shares. Proceeds are earmarked for research and development on Yarrow's pipeline — led by YB-101, a potential first-in-class antibody for Graves' disease and thyroid eye disease — plus general corporate purposes. Jefferies, TD Cowen and Guggenheim Securities are joint book-runners, with LifeSci Capital as lead manager, selling off a shelf registration effective August 19, 2026.
Key figures
- Seller
- all securities offered by Yarrow (primary offering)
- Securities offered
- common stock or pre-funded warrants
- Shelf registration
- Form S-3 declared effective August 19, 2026
- Overallotment option
- 30-day option for underwriters to purchase up to an additional 15% of shares at the public offering price
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.